Supernus Pharmaceuticals is set to acquire Sage Therapeutics
Please read the SEC documents regarding this current security and understand that I do own of these shares. This isn’t an offer or solicitation to buy shares.
https://investor.sagerx.com/node/14346/html#tm2518064d1_ex2-1.htm
https://investor.sagerx.com/sec-filings
Supernus Pharmaceuticals is set to acquire Sage Therapeutics, a company that has faced significant financial challenges despite having the only FDA-approved oral treatment for postpartum depression, ZURZUVAE. The deal, valued at up to $795 million, will see Supernus pay $8.50 per share in cash upfront, plus a (CVR) that could add another $3.50 per share based on ZURZUVAE's future sales.
CVR Milestone Payments (Maximum $3.50 per CVR):
Milestone 1: $1.00 per CVR if annual net sales of Zurzuvae allocable to Supernus equal at least $250 million in the U.S. by the end of 2027.
Milestone 2: $1.00 per CVR if annual net sales of Zurzuvae allocable to Supernus equal at least $300 million in the U.S. by the end of 2028.
Milestone 3: $1.00 per CVR if annual net sales of Zurzuvae allocable to Supernus reach $375 million in the U.S. by the end of 2030.
Milestone 4: $0.50 per CVR upon the first commercial sale in Japan to a third-party customer after regulatory approval for Zurzuvae in Japan for Major Depressive Disorder by June 30, 2026.
The stock is currently trading at $9.12
Here are some people whining to the board
All expressions of opinion reflect the judgment of the author and are subject to change. The information should not be construed as a recommendation. The foregoing content is subject to change at any time without notice content provided herein is for informational purposes only there is no guarantee these statements or forecasts will prove correct. past performance is no guarantee of future results. Investing involves risk including the possible loss of capital
.